N/A
Completed N=290
Promoting Engagement and COVID-19 Testing for Health
Source: ClinicalTrials.gov NCT06141850 ↗Enrolled (actual)
290
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcomePrimary: Number of Participants With Symptoms Who Use a COVID-19 Test — 16; 17; 3; 10 Participants
Summary
PEACH2 is a community-based study, targeting individuals affected by diabetes. Study participants will be randomized into the PEACH2 Intervention Arm or the Control Arm. The intervention lasts for 16 weeks and participants will be followed for 12 months in total.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Symptoms Who Use a COVID-19 Test |
16; 17; 3; 10; 6; 15 | — |
| SECONDARY Percent of Participants Receiving COVID-19 Vaccination |
83.4; 82.1; 85.6; 83.1; 90.0; 88.6 | — |
| SECONDARY Number of Participants Adhering to COVID-19 Prevention Behaviors |
78; 102; 44; 49; 20; 19 | — |
Eligibility Criteria
Inclusion Criteria
- English speaking
- Living in Georgia, USA
- Have access to a cellphone
- Not currently pregnant
- At-risk for diabetes, have diabetes, or are a family caregiver of someone living with diabetes
- Agree to receive text messages and be randomized to the intervention or control arm of the study
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT06141850). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.